Standard Guide for Analysis of Clandestine Drug Laboratory Evidence

SIGNIFICANCE AND USE
4.1 An analyst should be knowledgeable, through established laboratory training, of clandestine drug laboratory synthetic routes and the techniques used in the analysis of related samples. This acquired knowledge of clandestine drug laboratory samples assists the analyst in choosing the best analytical scheme to identify reagents, precursors, intermediates, and final products.  
4.2 The qualitative and quantitative analyses of clandestine drug laboratory evidence can require different approaches relative to routine seized drug analyses. Analysts shall understand the limitations of the procedures used in their qualitative and quantitative analyses. These include such factors as method selectivity, uncertainty, and the basis for inferences from a sample(s) to a population.  
4.3 Laboratory management shall ensure that clandestine drug laboratory synthesis and analysis training be provided through relevant procedures, literature, and practical experience. Practical experience typically includes production, sampling and analysis of clandestine drug laboratory training samples.  
4.4 Laboratory management shall ensure that chemical safety and hygiene plans address and mitigate hazards associated with clandestine drug laboratory evidence.  
4.5 It does not address scene attendance or scene processing.  
4.6 Laboratory management shall consider customer/local requirements which influence the application of these recommendations.
SCOPE
1.1 This standard is intended to be used in conjunction with the general requirements for the analysis of seized drugs (Practices E2326, E2327, E2329, and E2549; Guides E2548 and E2329). This standard provides guidance on the chemical analysis of items and samples related to suspected clandestine drug laboratories. This standard provides general guidance for the analysis of clandestine drug laboratory evidence and is not a substitute for detailed and validated laboratory policies and technical procedures.  
1.2 This standard cannot replace knowledge, skills, or abilities acquired through education, training, and experience (see Practice E2326) and is to be used in conjunction with professional judgment by individuals with such discipline-specific knowledge, skills, and abilities.  
1.3 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.  
1.4 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

General Information

Status
Published
Publication Date
31-Jul-2019
Technical Committee
Drafting Committee
Current Stage
Ref Project

Relations

Buy Standard

Guide
ASTM E2882-19 - Standard Guide for Analysis of Clandestine Drug Laboratory Evidence
English language
5 pages
sale 15% off
Preview
sale 15% off
Preview
Guide
REDLINE ASTM E2882-19 - Standard Guide for Analysis of Clandestine Drug Laboratory Evidence
English language
5 pages
sale 15% off
Preview
sale 15% off
Preview

Standards Content (Sample)

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the
Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
Designation: E2882 − 19 An American National Standard
Standard Guide for
1
Analysis of Clandestine Drug Laboratory Evidence
This standard is issued under the fixed designation E2882; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope E2327 Practice for Quality Assurance of Laboratories Per-
forming Seized-Drug Analysis
1.1 This standard is intended to be used in conjunction with
E2329 Practice for Identification of Seized Drugs
the general requirements for the analysis of seized drugs
E2363 Terminology Relating to ProcessAnalytical Technol-
(Practices E2326, E2327, E2329, and E2549; Guides E2548
ogy in the Pharmaceutical Industry
and E2329). This standard provides guidance on the chemical
E2548 Guide for Sampling Seized Drugs for Qualitative and
analysis of items and samples related to suspected clandestine
Quantitative Analysis
drug laboratories. This standard provides general guidance for
E2549 Practice for Validation of Seized-Drug Analytical
the analysis of clandestine drug laboratory evidence and is not
Methods
a substitute for detailed and validated laboratory policies and
F2725 Guide for European Union’s Registration,
technical procedures.
Evaluation, and Authorization of Chemicals (REACH)
1.2 This standard cannot replace knowledge, skills, or
Supply Chain Information Exchange
abilities acquired through education, training, and experience
(see Practice E2326) and is to be used in conjunction with
3. Terminology
professional judgment by individuals with such discipline-
3.1 Definitions of Terms Specific to This Standard:
specific knowledge, skills, and abilities.
3.1.1 capacity, n—the amount of finished product that could
1.3 This standard does not purport to address all of the
be produced, either in one batch or over a defined period of
safety concerns, if any, associated with its use. It is the
3
time, and given a set list of variables. SWGDRUG
responsibility of the user of this standard to establish appro-
priate safety, health, and environmental practices and deter-
3.1.2 catalyst, n—a substance whose presence initiates or
mine the applicability of regulatory limitations prior to use.
changestherateofachemicalreaction,butdoesnotitselfenter
1.4 This international standard was developed in accor-
into the reaction. D6161
dance with internationally recognized principles on standard-
3.1.3 finished product, n—a manufactured product ready for
ization established in the Decision on Principles for the
3
use. SWGDRUG
Development of International Standards, Guides and Recom-
mendations issued by the World Trade Organization Technical 3.1.4 intermediate, n—substance that is manufactured for
Barriers to Trade (TBT) Committee. and consumed in or used for chemical processing to be
transformed into another substance. F2725
2. Referenced Documents
3.1.5 reagent, n—a chemical used to react with another
2
2.1 ASTM Standards:
chemical, often to confirm or deny the presence of the second
D6161 Terminology Used for Microfiltration, Ultrafiltration,
chemical. E1605
Nanofiltration,andReverseOsmosisMembraneProcesses
3.1.6 yield, expected, n—the quantity of material or the
E1605 Terminology Relating to Lead in Buildings
percentage of theoretical yield anticipated at any appropriate
E2326 Practice for Education and Training of Seized-Drug
phase of production based on previous laboratory, pilot scale,
Analysts
or manufacturing data. E2363
3.1.7 yield, theoretical, n—the quantity that would be pro-
1
This guide is under the jurisdiction of ASTM Committee E30 on Forensic
duced at any appropriate phase of production based upon the
Sciences and is the direct responsibility of Subcommittee E30.01 on Criminalistics.
quantity of material to be used, in the absence of any loss or
Current edition approved Aug. 1, 2019. Published August 2019. Originally
error in actual production. E2363
approved in 2012. Last previous edition approved in 2012 as E2882 – 12. DOI:
10.1520/E2882-19.
2
For referenced ASTM standards, visit the ASTM website, www.astm.org, or
contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM
3
Standards volume information, refer to the standard’s Document Summary page on Available from the Scientific Working Group for theAnalysis of Seized Drugs,
the ASTM website. http://www.swgdrug.org.
Copyright © ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States
1

---------------------- Page: 1 ----
...

This document is not an ASTM standard and is intended only to provide the user of an ASTM standard an indication of what changes have been made to the previous version. Because
it may not be technically possible to adequately depict all changes accurately, ASTM recommends that users consult prior editions as appropriate. In all cases only the current version
of the standard as published by ASTM is to be considered the official document.
Designation: E2882 − 12 E2882 − 19
Standard Guide for
1
Analysis of Clandestine Drug Laboratory Evidence
This standard is issued under the fixed designation E2882; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope
1.1 This guidestandard is intended to be used in conjunction with the general requirements for the analysis of seized drugs
(Practices E2326, E2327, E2329, and E2549; Guides E2548 and E2329). This guidestandard provides guidance on the chemical
analysis of items and samples related to suspected clandestine drug laboratories. It does not address scene attendance or scene
processing. This documentThis standard provides general guidance for the analysis of clandestine drug laboratory evidence and
is not a substitute for detailed and validated laboratory policies and technical procedures.
1.2 This guide does not replace knowledge, skill, ability, experience, education, or training and should standard cannot replace
knowledge, skills, or abilities acquired through education, training, and experience (see Practice E2326) and is to be used in
conjunction with professional judgment.judgment by individuals with such discipline-specific knowledge, skills, and abilities.
1.3 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility
of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of
regulatory limitations prior to use.
1.4 This international standard was developed in accordance with internationally recognized principles on standardization
established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued
by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
2. Referenced Documents
2
2.1 ASTM Standards:
D6161 Terminology Used for Microfiltration, Ultrafiltration, Nanofiltration, and Reverse Osmosis Membrane Processes
E1605 Terminology Relating to Lead in Buildings
E2326 Practice for Education and Training of Seized-Drug Analysts
E2327 Practice for Quality Assurance of Laboratories Performing Seized-Drug Analysis
E2329 Practice for Identification of Seized Drugs
E2363 Terminology Relating to Process Analytical Technology in the Pharmaceutical Industry
E2548 Guide for Sampling Seized Drugs for Qualitative and Quantitative Analysis
E2549 Practice for Validation of Seized-Drug Analytical Methods
F2725 Guide for European Union’s Registration, Evaluation, and Authorization of Chemicals (REACH) Supply Chain
Information Exchange
3. Terminology
3.1 Definitions of Terms Specific to This Standard:
3.1.1 capacity—capacity, n—the amount of finished product that could be produced, either in one batch or over a defined period
3
of time, and given a set list of variables. SWGDRUG
3.1.2 catalyst—catalyst, n—a substance whose presence initiates or changes the rate of a chemical reaction, but does not itself
enter into the reaction. D6161
3
3.1.3 finished product—product, n—a manufactured product ready for use. SWGDRUG
1
This guide is under the jurisdiction of ASTM Committee E30 on Forensic Sciences and is the direct responsibility of Subcommittee E30.01 on Criminalistics.
Current edition approved Aug. 1, 2012Aug. 1, 2019. Published September 2012August 2019. Originally approved in 2012. Last previous edition approved in 2012 as
E2882 – 12. DOI: 10.1520/E2882-12.10.1520/E2882-19.
2
For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM Standards
volume information, refer to the standard’s Document Summary page on the ASTM website.
3
Available from the Scientific Working Group for the Analysis of Seized Drugs, http://www.swgdrug.org.
Copyright © ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States
1

---------------------- Page: 1 ----------------------
E2882 − 19
3.1.4 intermediate—intermediate, n—ubstancesubstance that is manufactured for and consumed in or used for chemical
processing to be transformed into another substance. F2725
3.1.5 reagent—reagent, n—a chemical used to react with another chemical, often to confirm or deny the presence of the second
chemical. E1605
3.1.6 yi
...

Questions, Comments and Discussion

Ask us and Technical Secretary will try to provide an answer. You can facilitate discussion about the standard in here.